Patents by Inventor Anitha Thomas
Anitha Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12636368Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery of nucleic acid and protein therapeutics for preparing and implementing T cell transfection, gene editing, cancer therapies, cancer prophylactics, and in the preparation of vaccines.Type: GrantFiled: June 26, 2020Date of Patent: May 26, 2026Assignee: GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULCInventors: Anitha Thomas, Nikita Jain, Andrew William Brown
-
Publication number: 20260078085Abstract: The present disclosure provides methods for modifying a cell. In one embodiment, the method includes: contacting the cell with a pharmaceutical composition including a nucleic acid payload encapsulated by a lipid mix composition having a compound of Formula (I), or a pharmaceutically acceptable salt thereof; and transfecting the nucleic acid payload into the cell.Type: ApplicationFiled: September 24, 2025Publication date: March 19, 2026Inventors: Nikita Jain, Anitha Thomas, Andrew William Brown
-
Patent number: 12503432Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic agents, or proteins, or both, and for delivery of nucleic acid and protein therapeutics to cells in vivo or ex vivo, including anticancer and vaccine applications.Type: GrantFiled: June 19, 2020Date of Patent: December 23, 2025Assignee: Global Life Sciences Solutions Canada ULCInventors: Nikita Jain, Anitha Thomas, Andrew William Brown
-
Publication number: 20250228926Abstract: Disclosed are recombinant expression vectors useful as RNA vaccines. Also disclosed are pharmaceutically acceptable carriers for the recombinant expression vectors, particularly lipid nanoparticles.Type: ApplicationFiled: October 7, 2022Publication date: July 17, 2025Inventors: Andy John Geall, Suraj Abraham, Anitha Thomas, Sitalakshmi Radhakrishnan Thampatty, Sijo Chemmannur
-
Patent number: 11679159Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.Type: GrantFiled: April 15, 2019Date of Patent: June 20, 2023Assignee: Precision Nanosystems ULCInventors: Anitha Thomas, Andrew William Brown, Rebecca Anne Grace De Souza, Tara L. Fernandez
-
Patent number: 11572575Abstract: A transfection reagent composition comprising: 30-60 MOL. % of a cationic lipid, or a pharmaceutical acceptable salt thereof; 10-60 MOL % of a structural lipid; 10-20 MOL % of a triglyceride; and 0.1 to about 10 MOL. % of a stabilizing agent, is provided. The transfection agent is effective in transfecting cells, particularly neurons, with siRNA, mRNA and plasmid nucleic acid, Sand maintaining viability of the cells as well as activity of the delivered nucleic acid.Type: GrantFiled: December 19, 2017Date of Patent: February 7, 2023Assignee: Precision NanoSystems ULCInventors: Anitha Thomas, Rebecca Anne Grace De Souza, Eric Ouellet, Grace Tharmini Tharmarajah, Jagbir Singh, Shyam Madhusudan Garg
-
Publication number: 20220396548Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic agents, or proteins, or both, and for delivery of nucleic acid and protein therapeutics to cells in vivo or ex vivo, including anticancer and vaccine applications.Type: ApplicationFiled: June 19, 2020Publication date: December 15, 2022Inventors: Nikita JAIN, Anitha THOMAS, Andrew William BROWN
-
Publication number: 20220378917Abstract: The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery of nucleic acid and protein therapeutics for preparing and implementing T cell transfection, gene editing, cancer therapies, cancer prophylactics, and in the preparation of vaccines.Type: ApplicationFiled: June 26, 2020Publication date: December 1, 2022Inventors: Anitha THOMAS, Nikita JAIN, Andrew William BROWN
-
Publication number: 20220162552Abstract: There is provided a lipid mix composition comprising ionizable lipid, a structural lipid such as DSPC, a sterol, and a surfactant such as polysorbate 80, polyoxyethylene (10) stearyl ether, polyoxyethylene (20) stearyl ether, or D-?-Tocopherol polyethylene glycol 1000 succinate. The lipid mix compositions find particular use in transfecting difficult to transfect cells and maintaining the viability of those cells. The lipid mix compositions are particularly well suited to T cell transfection ex vivo.Type: ApplicationFiled: April 14, 2020Publication date: May 26, 2022Applicant: Precision NanoSystems Inc.Inventors: Anitha Thomas, Andrew William Brown, Rebecca Anne Grace De Souza, Tara Fernandez
-
Publication number: 20210284998Abstract: A transfection reagent composition comprising: 30-60 MOL % of an cationic lipid, or pharmaceutical acceptable salt thereof; 10-60 MOL % structural lipid; a sterol and 0.1 to about 10 MOL % of a stabilizing agent is provided. The reagent is particularly adapted for neuron and related cell types. A method of manufacturing LNP including nucleic acid for selective uptake into either neurons or astrocytes or neural progenitor cells is also provided.Type: ApplicationFiled: October 2, 2017Publication date: September 16, 2021Applicant: Precision NanoSystems Inc.Inventors: Anitha Thomas, Rebecca Anne Grace De Souza, Eric Ouellet, Grace Tharmini Tharmarajah, Jagbir Singh, Shyam Madhusudan Garg
-
Publication number: 20210162052Abstract: A reagent composition for delivery nucleic acid therapeutics to cells is provided. The reagent includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable. The 5 transfection reagent is effective in plasmid and mRNA delivery, and in neurons and progenitor-like cells. It may be used for ex vivo cell therapy.Type: ApplicationFiled: April 15, 2019Publication date: June 3, 2021Applicant: Precision NanoSystems Inc.Inventors: Anitha Thomas, Andrew William Brown, Rebecca Anne Grace De Souza, Tara L. Fernandez
-
Patent number: 10597291Abstract: The present disclosure is directed towards a disposable microfluidic cartridge configured for use in a system for the small scale production of nanoparticles used in scientific research or therapeutic applications. The system can be used to produce a wide variety of nanoparticles, including but not limited to lipid and polymer nanoparticles, carrying a variety of payloads. The system provides for a simple workflow which in certain embodiments can be used to produce a sterile product.Type: GrantFiled: October 27, 2017Date of Patent: March 24, 2020Assignee: The University of British ColumbiaInventors: Andre Wild, Timothy Leaver, Colin Walsh, Gesine Heuck, Anitha Thomas, Aysha Ansari, Kevin Ou, Robert James Taylor, Euan Ramsay
-
Publication number: 20190292566Abstract: A transfection reagent composition comprising: 30-60 MOL. % of a cationic lipid, or a pharmaceutical acceptable salt thereof; 10-60 MOL % of a structural lipid; 10-20 MOL % of a triglyceride; and 0.1 to about 10 MOL. % of a stabilizing agent, is provided. The transfection agent is effective in transfecting cells, particularly neurons, with siRNA, mRNA and plasmid nucleic acid, Sand maintaining viability of the cells as well as activity of the delivered nucleic acid.Type: ApplicationFiled: December 19, 2017Publication date: September 26, 2019Applicant: Precision NanoSystems Inc.Inventors: Anitha Thomas, Rebecca Anne Grace De Souza, Eric Ouellet, Grace Tharmini Tharmarajah, Jagbir Singh, Shyam Madhusudan Garg
-
Publication number: 20180111830Abstract: The present disclosure is directed towards a disposable microfluidic cartridge configured for use in a system for the small scale production of nanoparticles used in scientific research or therapeutic applications. The system can be used to produce a wide variety of nanoparticles, including but not limited to lipid and polymer nanoparticles, carrying a variety of payloads. The system provides for a simple workflow which in certain embodiments can be used to produce a sterile product.Type: ApplicationFiled: October 27, 2017Publication date: April 26, 2018Applicant: The University of British ColumbiaInventors: Andre Wild, Timothy Leaver, Colin Walsh, Gesine Heuck, Anitha Thomas, Aysha Ansari, Kevin Ou, Robert James Taylor, Euan Ramsay
